% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • synergykjs synergykjs Mar 8, 2007 8:27 AM Flag

    Myriad initiates Azixa Phase 2

    No press release from EPCT yet

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • There are approximately 18,000 primary brain tumors and 180,000 new cases of metastasis to the brain in the United States each year, and the number of metastatic tumors has risen steadily as the treatment of primary tumors has improved. Glioblastoma multiforme (GBM) is by far the most common and most aggressive primary brain tumor. The standard of care for patients with GBM is primarily surgery and whole brain radiation. The 5 year survival rate of the disease has remained unchanged over the past 30 years, and stands at less than three percent. Even with complete surgical resection of the tumor, combined with the best available treatment, the survival rate for GBM remains very low. Most anticancer drugs are unable to cross the blood/brain barrier in sufficient concentration to achieve clinical benefit to the patient. There is currently no approved chemotherapy for metastatic brain cancer.

0.39-0.02(-4.08%)Jul 28 3:58 PMEDT